Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 25

Results For "oncology"

702 News Found

Apollo Cancer Centres heralds a new era in breast cancer surgery
Healthcare | March 27, 2024

Apollo Cancer Centres heralds a new era in breast cancer surgery

The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions


AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Diagnostic Center | March 23, 2024

AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer

Combination shows consistent benefit across prespecified post-progression outcomes


AstraZeneca buys biopharmaceutical company Fusion
News | March 20, 2024

AstraZeneca buys biopharmaceutical company Fusion

To accelerate the development of next-generation radioconjugates to treat cancer


Dr. Reddy's Laboratories launches Versavo in the UK
News | March 19, 2024

Dr. Reddy's Laboratories launches Versavo in the UK

Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK


Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr
News | March 17, 2024

Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr

Both organisations enter into a long- term collaboration to expand patient access in India


Sumitomo Pharma announces availability of ORGOVYX in Canada
News | March 17, 2024

Sumitomo Pharma announces availability of ORGOVYX in Canada

The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer


Zydus launches generic version of Olaparib ‘IBYRA’ in India
News | March 14, 2024

Zydus launches generic version of Olaparib ‘IBYRA’ in India

The drug will target specific genetic mutations prevalent in certain types of cancers


Merck completes acquisition of Harpoon Therapeutics
News | March 12, 2024

Merck completes acquisition of Harpoon Therapeutics

Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager


Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL
Diagnostic Center | March 12, 2024

Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL

Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS